U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H16N4O.ClH
Molecular Weight 256.732
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIDAMIDINE HYDROCHLORIDE

SMILES

Cl.CNC(=N)NC(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=INMBONSHXVMDSX-UHFFFAOYSA-N
InChI=1S/C11H16N4O.ClH/c1-7-5-4-6-8(2)9(7)14-11(16)15-10(12)13-3;/h4-6H,1-3H3,(H4,12,13,14,15,16);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C11H16N4O
Molecular Weight 220.2709
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lidamidine, also known as WHR-1142A and Lidaral, is an alpha2-adrenergic receptor agonist that inhibits intestinal secretion, reduces intestinal transit, and inhibits smooth muscle contraction. Lidamidine hydrochloride is used to treat diarrhoea and other gastrointestinal disorders. Lidamidine’s intestinal antisecretory effects are mediated through the activation of peripheral alpha-2 adrenoceptors. Lidamidine crosses the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha-2 effects that have limited the use of other alpha-2 adrenoceptor agonists in the intestinal tract.

CNS Activity

Curator's Comment: Lidamidine crosses the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha-2 effects that have limited the use of other alpha-2 adrenoceptor agonists in the intestinal tract.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Lidarral

Approved Use

Lidamidine Hydrochloride. Lidamidine is an alpha2-adrenergic receptor stimulant used as the hydrochloride for the management of diarrhoea and other gastrointestinal disorders.
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Lidamidine HCL (4 mg) or placebo was taken orally t.i.d. with food. Lidamidine decreased the augmented mechanical response to food, reduced rectal sensitivity, and relieved symptoms of patients with irritable bowel syndrome.
Route of Administration: Oral
In Vitro Use Guide
The effects of clonidine and lidamidine on ion transport in the intestine of the rabbit were determined. In the ileum both clonidine (10(-6) M) and lidamidine (10(-3) M) (a) decreased the short circuit current (-1.9 +/- 0.3 and -2.0 +/- 0.4 muEq/h . cm2, respectively) and potential difference; (b) increased net sodium absorption (2.0 +/- 0.6 and 1.8 +/- 0.4 muEq/h . cm2) and chloride absorption (3.4 +/- 0.5 and 3.4 +/- 0.6 muEq/h . cm2); and (c) increased tissue conductance (8.7 +/- 1.7 and 10.0 +/- 1.6 mmho/cm2).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:14:36 UTC 2023
Edited
by admin
on Fri Dec 15 15:14:36 UTC 2023
Record UNII
3Q1Q4QJV3V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIDAMIDINE HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
LIDAMIDINE HYDROCHLORIDE [MART.]
Common Name English
LIDAMIDINE HYDROCHLORIDE [MI]
Common Name English
Lidamidine Hydrochloride [WHO-DD]
Common Name English
LIDAMIDINE HCL
Common Name English
WHR-1142A
Code English
LIDAMIDINE HYDROCHLORIDE [USAN]
Common Name English
1-(Methylamidino)-3-(2,6-xylyl)urea monohydrochloride
Systematic Name English
UREA, N-(2,6-DIMETHYLPHENYL)-N'-(IMINO(METHYLAMINO)METHYL)-, MONOHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C266
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
Code System Code Type Description
SMS_ID
100000128598
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
MERCK INDEX
m6804
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY Merck Index
FDA UNII
3Q1Q4QJV3V
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL448416
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID10983557
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
EVMPD
SUB35843
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
PUBCHEM
47509
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
CAS
65009-35-0
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
ECHA (EC/EINECS)
265-307-6
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
NCI_THESAURUS
C82241
Created by admin on Fri Dec 15 15:14:36 UTC 2023 , Edited by admin on Fri Dec 15 15:14:36 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY